What they do: Services-Medical Laboratories · Exchange: Nasdaq · Employees: 713
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California. (via Yahoo Finance)
| Quarter end | Revenue | Diluted EPS |
|---|---|---|
| 2024-09-30 | $38.4M | $-1.47 |
| 2025-03-31 | $59.0M | $-0.39 |
| 2025-06-30 | $66.6M | $-0.02 |
| 2025-09-30 | $83.5M | $0.10 |
| 2026-03-31 | $108.4M | $0.34 |
| 2026-06-30 | $109.4M | $0.15 |
Insiders hold: 28.34% · Institutions hold: 45.57% across 198 filers
| Institution | Shares | Value | % held |
|---|---|---|---|
| Adams Street Partners, LLC | 1,711,430 | $161.6M | 4.01% |
| Price (T.Rowe) Associates Inc | 1,010,322 | $95.4M | 2.37% |
| BAILLIE GIFFORD & CO | 901,420 | $85.1M | 2.11% |
| Vanguard Portfolio Management LLC | 840,970 | $79.4M | 1.97% |
| Invesco Ltd. | 835,614 | $78.9M | 1.96% |
| Vanguard Capital Management LLC | 799,468 | $75.5M | 1.87% |
| Neuberger Berman Group, LLC | 764,215 | $72.2M | 1.79% |
| BAMCO Inc. | 742,093 | $70.1M | 1.74% |
| Trade date | Filed | Name | Role | Action | Shares | Price | Value | Stock since |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | OPTION EXERCISE | 10,000 | $2.80 | $28K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 20 | $110.08 | $2K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 100 | $110.09 | $11K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 400 | $106.10 | $42K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 555 | $105.56 | $59K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 866 | $105.90 | $92K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 1,829 | $109.14 | $200K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 1,909 | $107.19 | $205K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 2,200 | $107.47 | $236K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 2,921 | $109.00 | $318K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 4,284 | $108.39 | $464K | -13.4% |
| 2026-10-05 | 2026-10-07 | Tsao David | Chief Technology Officer | SOLD | 4,916 | $108.53 | $534K | -13.4% |
| 2026-10-05 | 2026-10-07 | ten Bosch John Roderick | SVP of Laboratory Operations | SOLD | 1,417 | $105.15 | $149K | -13.4% |